Rein Therapeutics (RNTX)
Develops peptide candidates for pulmonary fibrosis and related lung diseases.
Something off on this page? Send us feedback.
Develops peptide candidates for orphan pulmonary and fibrosis indications. Its lead program, LTI-03, is in a Phase 2 trial for idiopathic pulmonary fibrosis, while LTI-01 has completed earlier studies for loculated pleural effusions.
Develops peptide therapies for orphan pulmonary and fibrosis indications. Its lead candidate, LTI-03, is being evaluated in the randomized, placebo-controlled Phase 2 RENEW trial for idiopathic pulmonary fibrosis; enrollment spans planned sites in five countries. LTI-01, a second candidate for loculated pleural effusions, has completed earlier Phase 1b and Phase 2a studies.
Clinical execution is centered on LTI-03 following the 2023 acquisition of Lung Therapeutics and the 2025 Rein rebrand. The company’s stated use of recent offering proceeds includes completing the LTI-03 trial, alongside clinical, manufacturing, and regulatory activities. Its present business therefore depends on advancing a small, pulmonary-focused clinical pipeline through development.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Jan 21, 2026 | Brookline Capital | Downgrade | Buy | Hold | |
| Nov 3, 2025 | Loop Capital Markets | Target | $6 | ||
| Aug 19, 2025 | Brookline Capital | Downgrade | Buy | Hold |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $40.6M · Total debt $0 · Total assets $66.0M · Shareholders' equity $10.2M
- Revenue
- $0
- Operating income
- −$6.1M
- Net income
- −$6.4M
No dividends on record.
| Institutions45 holders · as of Mar 31, 2026 | 13.21% | 11.40M shares | |
| Insiders2 holders · as of May 28, 2026 | 0.10% | 89.6K shares | |
| Strategic holders2 holders · as of Aug 14, 2026 | 10.72% | 9.25M shares | |
| Otherremainder | 75.97% | 65.53M shares |
86.27M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (86.27M in the company's Sep 3, 2026 report, 27.96M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Funicular Funds, LPInstitution | 6.02% | 5.20M | 13Gfiled May 7, 2026 ↗ |
Lynwood Capital Management Inc.Strategic | 5.51% | 4.75M | 13Gfiled May 8, 2026 ↗ |
ADAR1 Capital Management, LLCStrategic | 5.22% | 4.50M | 13Gfiled Aug 14, 2026 ↗ |
Voss Capital, LPInstitution | 5.09% | 4.39M | 13Fas of Mar 31, 2026 |
Bios Capital Management, LPInstitution | 2.30% | 1.98M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 21, 2026 | Josef H. von Rickenbach | director | +3,420 | $1.04 |
| May 22, 2026 | Josef H. von Rickenbach | director | +15,950 | $1.05 |
| May 26, 2026 | Josef H. von Rickenbach | director | +23,190 | $1.06 |
| May 27, 2026 | Josef H. von Rickenbach | director | +4,500 | $1.07 |
| Apr 30, 2026 | James Brian Windsor | director, officer: See Remarks | +25,000 | $1.00 |
- United Therapeutics
Late-stage inhaled Tyvaso program targets IPF lung function.
- Bristol-Myers Squibb
Phase 3 admilparant program addresses IPF and lung-function decline.
- Contineum Therapeutics
Global Phase 2 PIPE-791 trial competes for IPF development and sites.
- Trevi Therapeutics
Planned pivotal Haduvio trials target chronic cough in IPF.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Rein Therapeutics | $0.7748 | +2.94% | $21.7M | — | — | — | — |
| United Therapeutics | $480.00 | −2.43% | $20.88B | 17.6 | 18.9 | 6.6 | −1.9% |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Contineum Therapeutics | $17.24 | +4.14% | $648.6M | — | — | — | — |
| Trevi Therapeutics | $17.07 | +3.02% | $2.42B | — | — | — | — |
| Median | 16.3 | 14.8 | 4.7 | +1.9% |